相关实验视频

Updated: Jun 26, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

封装在新型CD25向纳米脂质体中的Foxp3抑制可以促进小鼠有效的瘤回归

Alejandro Serrano^1,2, Noelia Casares^2,3, Iñaki F Trocóniz^1,2

¹Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.

Acta pharmacologica Sinica

|July 29, 2024

概括

这项研究开发了向免疫聚体 (IL-P60_750) 以改善Foxp3抑制P60的稳定性和传递,用于癌症免疫疗法. 这种新型配方通过选择性抑制调节性T细胞活性和增强抗PD-1疗法,显示出显著的抗瘤疗效.

科学领域:

免疫学免疫学免疫学
纳米技术纳米技术
癌症研究癌症研究

背景情况:

调控性T细胞 (Tregs) 抑制抗瘤免疫力.
P60抑制Treg活性,但稳定性和特异性较差.
目前的P60疗法需要频繁的剂量由于局限性.

研究的目的:

加强P60的稳定性,并实现对Tregs.的有针对性的交付.
开发针对Tregs的CD25的P60载荷脂质体 (免疫脂质体,IL).
为了评估新型免疫脂质体配方的抗瘤疗效.

主要方法:

配制P60载荷脂质体,具有不同的DSPE-PEG链长度.
将结合的抗CD25 Fab'片段与脂质体结合,以产生向的免疫脂质体 (IL-P60_750和IL-P60_2000).
在小鼠模型中评估了Treg吸收,P60封装效率,T细胞增殖和体内抗瘤反应.

主要成果:

无论PEG长度如何,P60封装效率为50%-60%.
与IL-P60_2000和非向脂质体相比,IL-P60_750的Treg吸收显著更高.
在40%的小鼠中,IL-P60_750单一治疗诱导了瘤的完全回归,并增强了抗PD-1联合治疗的疗效.

结论:

IL-P60_750配方显示了改善的稳定性和针对性的P60.0.的交付.
这种有针对性的方法可以选择性地抑制Treg活性,增强抗瘤免疫反应.
IL-P60_750代表了一个有前途的纳米平台,用于推进癌症免疫疗法.

关键词:

CD25 CD25 CD25 CD25 CD25 CD25 CD25 CD25 CD25 CD25 CD25 CD25 PEG 链条的长度在Treg细胞中.脂质纳米颗粒是一种纳米粒子.在插入后的插入后.翻译方法翻译方法

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.